DRI HEALTHCARE TRUST (DHT-U.CA) Stock Price, Forecast & Analysis
Canada - TSX:DHT-U - CA23344H1091
11.3 USD
+0.59 (+5.51%)
We assign a fundamental rating of 5 out of 10 to DHT-U. DHT-U was compared to 32 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of DHT-U get a neutral evaluation. Nothing too spectacular is happening here. DHT-U may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
DHT-U had positive earnings in the past year.
DHT-U had a positive operating cash flow in the past year.
1.2 Ratios
Looking at the Return On Assets, with a value of 0.41%, DHT-U is in the better half of the industry, outperforming 71.88% of the companies in the same industry.
DHT-U has a Return On Equity of 0.78%. This is in the better half of the industry: DHT-U outperforms 71.88% of its industry peers.
DHT-U's Return On Invested Capital of 3.82% is fine compared to the rest of the industry. DHT-U outperforms 68.75% of its industry peers.
The Average Return On Invested Capital over the past 3 years for DHT-U is significantly below the industry average of 7.63%.
The last Return On Invested Capital (3.82%) for DHT-U is above the 3 year average (1.94%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.41% | ||
| ROE | 0.78% | ||
| ROIC | 3.82% |
ROA(3y)4.16%
ROA(5y)N/A
ROE(3y)6.27%
ROE(5y)N/A
ROIC(3y)1.94%
ROIC(5y)N/A
1.3 Margins
DHT-U has a Profit Margin of 2.11%. This is in the better half of the industry: DHT-U outperforms 75.00% of its industry peers.
DHT-U has a better Operating Margin (25.45%) than 90.63% of its industry peers.
In the last couple of years the Operating Margin of DHT-U has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.45% | ||
| PM (TTM) | 2.11% | ||
| GM | N/A |
OM growth 3Y-6.12%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so DHT-U is destroying value.
Compared to 1 year ago, DHT-U has about the same amount of shares outstanding.
The debt/assets ratio for DHT-U is higher compared to a year ago.
2.2 Solvency
DHT-U has an Altman-Z score of 1.18. This is a bad value and indicates that DHT-U is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of DHT-U (1.18) is better than 71.88% of its industry peers.
DHT-U has a debt to FCF ratio of 3.05. This is a good value and a sign of high solvency as DHT-U would need 3.05 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.05, DHT-U belongs to the top of the industry, outperforming 90.63% of the companies in the same industry.
A Debt/Equity ratio of 0.77 indicates that DHT-U is somewhat dependend on debt financing.
DHT-U's Debt to Equity ratio of 0.77 is on the low side compared to the rest of the industry. DHT-U is outperformed by 71.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | 3.05 | ||
| Altman-Z | 1.18 |
ROIC/WACC0.5
WACC7.59%
2.3 Liquidity
DHT-U has a Current Ratio of 1.83. This is a normal value and indicates that DHT-U is financially healthy and should not expect problems in meeting its short term obligations.
DHT-U's Current ratio of 1.83 is in line compared to the rest of the industry. DHT-U outperforms 53.13% of its industry peers.
DHT-U has a Quick Ratio of 1.83. This is a normal value and indicates that DHT-U is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Quick ratio value of 1.83, DHT-U is doing good in the industry, outperforming 78.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.83 |
3. Growth
3.1 Past
DHT-U shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -11.89%.
The Earnings Per Share has been growing slightly by 5.09% on average over the past years.
DHT-U shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.24%.
The Revenue has been growing by 32.25% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-11.89%
EPS 3Y5.09%
EPS 5YN/A
EPS Q2Q%4.08%
Revenue 1Y (TTM)16.24%
Revenue growth 3Y32.25%
Revenue growth 5YN/A
Sales Q2Q%6.07%
3.2 Future
DHT-U is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.64% yearly.
DHT-U is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.41% yearly.
EPS Next Y-4.59%
EPS Next 2Y3.65%
EPS Next 3Y6.08%
EPS Next 5Y10.64%
Revenue Next Year10.56%
Revenue Next 2Y5.58%
Revenue Next 3Y3.77%
Revenue Next 5Y9.41%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
DHT-U is valuated cheaply with a Price/Earnings ratio of 5.26.
Compared to the rest of the industry, the Price/Earnings ratio of DHT-U indicates a rather cheap valuation: DHT-U is cheaper than 93.75% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 25.47, DHT-U is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 4.85, the valuation of DHT-U can be described as very cheap.
Based on the Price/Forward Earnings ratio, DHT-U is valued cheaper than 93.75% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.42, DHT-U is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.26 | ||
| Fwd PE | 4.85 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, DHT-U is valued cheaply inside the industry as 87.50% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, DHT-U is valued cheaper than 84.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.27 | ||
| EV/EBITDA | 6.62 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.65%
EPS Next 3Y6.08%
5. Dividend
5.1 Amount
DHT-U has a Yearly Dividend Yield of 4.57%, which is a nice return.
DHT-U's Dividend Yield is rather good when compared to the industry average which is at 3.64. DHT-U pays more dividend than 100.00% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.44, DHT-U pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.57% |
5.2 History
DHT-U has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y3.65%
EPS Next 3Y6.08%
TSX:DHT-U (11/14/2025, 7:00:00 PM)
11.3
+0.59 (+5.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners56.4%
Inst Owner ChangeN/A
Ins Owners0.89%
Ins Owner ChangeN/A
Market Cap623.65M
Revenue(TTM)186.77M
Net Income(TTM)3.93M
Analysts80
Price Target14.57 (28.94%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.57% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.16%
Min EPS beat(2)-21.52%
Max EPS beat(2)5.2%
EPS beat(4)3
Avg EPS beat(4)6.36%
Min EPS beat(4)-21.52%
Max EPS beat(4)39.35%
EPS beat(8)5
Avg EPS beat(8)18.78%
EPS beat(12)7
Avg EPS beat(12)90.93%
EPS beat(16)8
Avg EPS beat(16)66.47%
Revenue beat(2)0
Avg Revenue beat(2)-0.5%
Min Revenue beat(2)-0.64%
Max Revenue beat(2)-0.37%
Revenue beat(4)2
Avg Revenue beat(4)14.3%
Min Revenue beat(4)-0.64%
Max Revenue beat(4)46.19%
Revenue beat(8)5
Avg Revenue beat(8)27.34%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)1.35%
EPS NQ rev (3m)18.42%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.35%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.14%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.26 | ||
| Fwd PE | 4.85 | ||
| P/S | 3.34 | ||
| P/FCF | 4.27 | ||
| P/OCF | 4.27 | ||
| P/B | 1.24 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.62 |
EPS(TTM)2.15
EY19.03%
EPS(NY)2.33
Fwd EY20.63%
FCF(TTM)2.65
FCFY23.44%
OCF(TTM)2.65
OCFY23.44%
SpS3.38
BVpS9.12
TBVpS-4.91
PEG (NY)N/A
PEG (5Y)N/A
Graham Number21.01
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.41% | ||
| ROE | 0.78% | ||
| ROCE | 5.31% | ||
| ROIC | 3.82% | ||
| ROICexc | 4.21% | ||
| ROICexgc | 90.74% | ||
| OM | 25.45% | ||
| PM (TTM) | 2.11% | ||
| GM | N/A | ||
| FCFM | 78.26% |
ROA(3y)4.16%
ROA(5y)N/A
ROE(3y)6.27%
ROE(5y)N/A
ROIC(3y)1.94%
ROIC(5y)N/A
ROICexc(3y)2.05%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.74%
ROCE(5y)N/A
ROICexgc growth 3Y44.9%
ROICexgc growth 5YN/A
ROICexc growth 3Y-7.25%
ROICexc growth 5YN/A
OM growth 3Y-6.12%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.19
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | 3.05 | ||
| Debt/EBITDA | 2.61 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 97.99% | ||
| Profit Quality | 3716.37% | ||
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.83 | ||
| Altman-Z | 1.18 |
F-Score6
WACC7.59%
ROIC/WACC0.5
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-11.89%
EPS 3Y5.09%
EPS 5YN/A
EPS Q2Q%4.08%
EPS Next Y-4.59%
EPS Next 2Y3.65%
EPS Next 3Y6.08%
EPS Next 5Y10.64%
Revenue 1Y (TTM)16.24%
Revenue growth 3Y32.25%
Revenue growth 5YN/A
Sales Q2Q%6.07%
Revenue Next Year10.56%
Revenue Next 2Y5.58%
Revenue Next 3Y3.77%
Revenue Next 5Y9.41%
EBIT growth 1Y343.32%
EBIT growth 3Y24.15%
EBIT growth 5YN/A
EBIT Next Year104.78%
EBIT Next 3Y26.53%
EBIT Next 5Y23.58%
FCF growth 1Y103.46%
FCF growth 3Y19.16%
FCF growth 5YN/A
OCF growth 1Y103.46%
OCF growth 3Y19.16%
OCF growth 5YN/A
DRI HEALTHCARE TRUST / DHT-U.CA FAQ
What does DHT-U do?
DRI Healthcare Trust is an unincorporated open-ended company. The company is headquartered in Toronto, Ontario and currently employs 36 full-time employees. The company went IPO on 2021-02-11. The firm provides capital to universities and research institutions, academic institutions, biotechnology companies and pharmaceutical companies. The company acquires more than 75 royalties on 45-plus drugs, including Ekterly, Eylea, Keytruda, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. Its portfolio includes Empaveli/Syfovre, Eylea I, Eylea II, Natpara, Omidria, Oracea, Orserdu I, Orserdu II, Rydapt, Spinraza, Stelara, Vonjo I, Vonjo II, Xenpozyme, Xolair, Zejula, Zytiga, and other products. Its therapeutic areas include oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, lysosomal storage disorders (LSD) and immunology. The firm is managed by DRI Capital Inc. Its products are marketed by pharmaceutical companies, including Regeneron, Bayer, Santen; AstraZeneca; Galderma, and others.
What is the current price of DHT-U stock?
The current stock price of DHT-U.CA is 11.3 USD. The price increased by 5.51% in the last trading session.
How is the ChartMill rating for DRI HEALTHCARE TRUST?
DHT-U.CA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.